Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer
Circulating IL-8 and anti-IL-8 autoantibody in patients with ovarian cancer
复制标题
DOI：
10.1016/j.ygyno.2005.12.011
复制
发表时间：
2006-08-01
影响因子：
4.7
通讯作者：
Gorelik, Elieser
中科院分区：
文献类型：
--
作者：
Lokshin, Anna E.;Winans, Mathew;Gorelik, Elieser
目标.在正在进行的努力，以确定诊断卵巢癌的生物标志物，SEREX（重组cDNA表达文库的血清学分析）技术，导致检测20个已知基因，9个EST和一个新的序列。白细胞介素-8（IL-8）是SEREX筛选鉴定的卵巢癌相关抗原之一。因此，本研究的目的是评估循环抗IL-8抗体作为卵巢癌生物标志物的潜在重要性。我们建立并优化了一种新的免疫荧光微球检测血清中抗IL-8抗体的方法。应用磁珠法检测了44例早期卵巢癌患者、50例晚期卵巢癌患者、37例盆腔良性肿块患者和80例健康妇女血清中IL-8和抗IL-8 IgG浓度。我们的数据表明，血清中含有IL-8细胞因子，抗IL-8抗体，IL-8：抗IL-8复合物。我们发现，与健康对照组相比，卵巢癌患者血清中IL-8和抗IL-8抗体的浓度升高。对I-II期卵巢癌患者与健康对照者的抗IL-8 IgG循环浓度进行Logistic回归分析，预测早期卵巢癌的特异性为98%，敏感性为65.5%，正确分类的患者为80.3%。IL-8和抗IL-8 IgG与CA 125的组合导致与单独分析的单个标志物相比增加的分类能力。因此，IL-8和抗IL-8自身抗体可能作为卵巢癌的额外生物标志物。(c)2005年爱思唯尔公司All rights reserved.
Objectives. In an ongoing effort to identify diagnostic ovarian cancer biomarkers, SEREX (serological analysis of recombinant cDNA expression libraries) technique was employed resulting in detection of 20 known genes, nine ESTs and one novel sequence. Interleukin-8 (IL-8) was one of ovarian cancer-associated antigens identified by SEREX screening. The objective of this study was, therefore, to evaluate the potential importance of circulating anti-IL-8 antibody as ovarian cancer biomarker.Methods. We developed and optimized a new immunofluorescent bead-based assay for detection of anti-IL-8 antibody in blood serum. Circulating IL-8 and anti-IL-8 IgG concentrations were measured in blood sera from 44 patients with early stage (I-II) ovarian cancer, 50 patients with late stage (III-IV) ovarian cancer, 37 patients with benign pelvic masses, and 80 healthy women using the bead-based assay.Results. Our data indicate that serum contains IL-8 cytokine, anti-IL-8 antibody, and IL-8:anti-IL-8 complexes. We found that concentrations of IL-8 and anti-IL-8 antibody were elevated in sera of patients with ovarian cancer as compared with healthy controls. Logistic regression analysis of circulating concentrations of anti-IL-8 IgG in patients with stages I-II ovarian cancer versus healthy controls allowed for prediction of early ovarian cancer with 98% specificity, 65.5% sensitivity, 80.3% of patients correctly classified. Combining IL-8 and anti-IL-8 IgG with CA 125 resulted in increased classification power as compared to individual markers analyzed separately.Conclusion. Thus, IL-8 and anti-IL-8 autoantibody might potentially serve as additional biomarkers for ovarian cancer. (c) 2005 Elsevier Inc. All rights reserved.